Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996669 · ClinicalTrials.gov registry record
Autism Biomarker Consortium for Clinical Trials
A clinical trial of Autism Spectrum Disorder, sponsored by Yale University.
- Completed
- Registry status
- 399
- Enrollment target
- 1
- Study location
NCT02996669 is a study of Autism Spectrum Disorder that has completed, run by Yale University. The registered enrollment target is 399 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (198% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02996669, a study of Autism Spectrum Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 399 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter longitudinal study that aims to identify, develop and validate a set of measures that can be used as stratification biomarkers and/or sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) that could serve as markers of long term clinical outcome. The main study will include 275 individuals: 200 ASD subjects between 6-11 years old, and 75 TD subjects roughly matched by age and sex to the ASD group.
Conditions Studied
Study Locations (1)
Connecticut
- Yale University Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-05-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996669
The ClinicalTrials.gov registry entry for NCT02996669 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (198% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT02996669 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02996669 about?
NCT02996669 is a clinical study titled "Autism Biomarker Consortium for Clinical Trials". This is a multicenter longitudinal study that aims to identify, develop and validate a set of measures that can be used as stratification biomarkers and/or sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) that could serve as markers of long term clini...
What is the current status of trial NCT02996669?
This trial is currently completed. The enrollment target is 399 participants. The study started on 2016-10. Estimated completion is 2019-05-13.
What conditions does trial NCT02996669 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
Who is sponsoring clinical trial NCT02996669?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996669 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.